During the past decade, IRCCS Istituto tumori Giovanni Paolo II conducted 72 clinical trials. In the 10-year time frame, 72 clinical trials started and 25 clinical trials were completed, i.e. on average, 34.7% percent of trials that started reached the finish line to date. In the past 5 years, 39 clinical trials started and 14 clinical trials were completed. i.e. 35.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "IRCCS Istituto tumori Giovanni Paolo II" #1 sponsor was "Hoffmann-La Roche" with 22 trials, followed by "Incyte Corporation" with 9 trials sponsored, "Consorzio Oncotech" with 4 trials sponsored, "Fondazione Ricerca Traslazionale" with 4 trials sponsored and "Fondazione Italiana Linfomi ONLUS" with 4 trials sponsored. Other sponsors include 47 different institutions and companies that sponsored additional 43 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "IRCCS Istituto tumori Giovanni Paolo II" #1 collaborator was "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "Clinical Research Technology S.r.l." with 2 trials as a collaborator and "Hoffmann-La Roche" with 2 trials as a collaborator. Other collaborators include 41 different institutions and companies that were collaborators in the rest 49 trials.

According to Clinical.Site data, the most researched conditions in "IRCCS Istituto tumori Giovanni Paolo II" are "Melanoma" (5 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials), "Follicular Lymphoma" (4 trials), "Malignant Melanoma" (4 trials) and "Breast Cancer" (3 trials). Many other conditions were trialed in "IRCCS Istituto tumori Giovanni Paolo II" in a lesser frequency.

Most popular intervention types in "IRCCS Istituto tumori Giovanni Paolo II" are "Drug" (78 trials), "Biological" (6 trials), "Other" (5 trials), "Procedure" (5 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Rituximab" (7 trials), "Atezolizumab" (6 trials), "Carboplatin" (6 trials) and "Pembrolizumab" (6 trials). Other intervention names were less common.

The vast majority of trials in "IRCCS Istituto tumori Giovanni Paolo II" are 86 trials for "All" genders, 7 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "IRCCS Istituto tumori Giovanni Paolo II". 1 are not yet recruiting, 23 are recruiting, 22 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in IRCCS Istituto tumori Giovanni Paolo II, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in IRCCS Istituto tumori Giovanni Paolo II, 1 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 51 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".